The estimated Net Worth of Mansoor Raza Mirza is at least $1.48 Milhão dollars as of 18 December 2020. Mansoor Mirza owns over 5,000 units of Karyopharm Therapeutics Inc stock worth over $3,700 and over the last 11 years he sold KPTI stock worth over $1,283,085. In addition, he makes $196,774 as Director and Clinical Advisor at Karyopharm Therapeutics Inc.
Mansoor has made over 23 trades of the Karyopharm Therapeutics Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently he exercised 5,000 units of KPTI stock worth $27,150 on 18 December 2020.
The largest trade he's ever made was exercising 20,000 units of Karyopharm Therapeutics Inc stock on 7 December 2020 worth over $108,600. On average, Mansoor trades about 3,356 units every 64 days since 2013. As of 18 December 2020 he still owns at least 5,000 units of Karyopharm Therapeutics Inc stock.
You can see the complete history of Mansoor Mirza stock trades at the bottom of the page.
Dr. Mansoor Raza Mirza M.D. serves as Director and Clinical Advisor of the Company. He serves as Director and Clinical Advisor of the Company. serves as Director and Clinical Advisor of the Company. Dr. Mirza is Chief Oncologist at the Department of Oncology, Rigshopitalet—the Copenhagen University Hospital, Denmark and Medical Director of the Nordic Society of Gynaecological Oncology, or NSGO. Dr. Mirza is Chairman of the European Network of Gynaecological Oncological Trial groups, or ENGOT. Dr. Mirza is both a medical and radiation oncologist, with a primary focus in non-surgical treatment of gynecologic cancers. His key academic goals are to promote clinical research, international trial collaboration and education, and he has broad experience in clinical protocol development, trial conduct and clinical trial regulations. He has multiple publications in high-impact journals (>100), including several publications in the New England Journal of Medicine and the Lancet. He holds a M.D., Diploma in Surgery and Diploma in Clinical Oncology from the Pirogov Moscow State Medical Institute as well as post-graduate education and certification in radiation and medical oncology from the University of Southern Denmark. Mirza’s qualifications to serve on our Board include his expertise in the non-surgical treatment of cancer, and gynecologic cancers in particular, and his knowledge of our company and its business through service on our Board since 2010.
As the Director and Clinical Advisor of Karyopharm Therapeutics Inc, the total compensation of Mansoor Mirza at Karyopharm Therapeutics Inc is $196,774. There are 9 executives at Karyopharm Therapeutics Inc getting paid more, with Ran Frenkel having the highest compensation of $6,481,860.
Mansoor Mirza is 59, he's been the Director and Clinical Advisor of Karyopharm Therapeutics Inc since . There are 5 older and 18 younger executives at Karyopharm Therapeutics Inc. The oldest executive at Karyopharm Therapeutics Inc is Garen Bohlin, 72, who is the Independent Director.
Mansoor's mailing address filed with the SEC is C/O KARYOPHARM THERAPEUTICS INC., 85 WELLS AVENUE, NEWTON, MA, 02459.
Over the last 11 years, insiders at Karyopharm Therapeutics Inc have traded over $149,223,596 worth of Karyopharm Therapeutics Inc stock and bought 562,763 units worth $10,312,371 . The most active insiders traders include Deepika Pakianathan, Ltd Czernik Marcin Hadjimic..., eMikael Dolsten. On average, Karyopharm Therapeutics Inc executives and independent directors trade stock every 12 days with the average trade being worth of $26,350. The most recent stock trade was executed by Michael Mano on 4 September 2024, trading 3,971 units of KPTI stock currently worth $2,859.
karyopharm therapeutics inc. is a clinical-stage pharmaceutical company focused on discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases. for more information, please visit www.karyopharm.com
Karyopharm Therapeutics Inc executives and other stock owners filed with the SEC include: